Helsinki Business and Science Park Ltd, HBSP
Viikinkaari 4, FIN-00790 Helsinki, Finland
Viikinkaari 4, FIN-00790 Helsinki, Finland
T +358 400 838 115
F +358 9 3193 6554
F +358 9 3193 6554
17/06/2010
Oncolytic viruses mediating anti-tumor immunity in human cancer patients published by Oncos Therapeutics and University of Helsinki
Oncos Therapeutics, a biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published today initial results from its Advanced Therapy Access Program in Cancer Research.
The results demonstrate anti-tumor immunity of oncolytic viruses – published for the first time in humans – and indicate strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company’s Advanced Therapy Access Program.
“This is the first time it has been shown in humans that oncolytic viruses can be used for induction of anti-tumor immunity. The GMCSF –armed oncolytic adenovirus can mediate anti-tumor immunologic responses by recruiting natural killer cells and by induction of tumor-specific cytotoxic T-cells”, explains research professor Akseli Hemminki, CSO and co-founder of Oncos.
Read the press release here